<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-id journal-id-type="publisher-id">TEMI</journal-id><journal-id journal-id-type="publisher-id">temi20</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32378471</article-id><article-id pub-id-type="publisher-id">1764871</article-id><article-id pub-id-type="doi">10.1080/22221751.2020.1764871</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Animal models for emerging coronavirus: progress and new insights</article-title><alt-title alt-title-type="running-title">EMERGING MICROBES AND INFECTIONS</alt-title><alt-title alt-title-type="running-authors">L. YUAN ET AL.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Lunzhi</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref><xref ref-type="author-notes" rid="an1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6487-2356</contrib-id><name><surname>Tang</surname><given-names>Qiyi</given-names></name><xref ref-type="aff" rid="AF2"><sup>b</sup></xref><xref ref-type="author-notes" rid="an1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1638-6214</contrib-id><name><surname>Cheng</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref><xref ref-type="corresp" rid="cor1"><sup>CONTACT</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0179-5266</contrib-id><name><surname>Xia</surname><given-names>Ningshao</given-names></name><xref ref-type="aff" rid="AF1"><sup>a</sup></xref><xref ref-type="corresp" rid="cor2"/></contrib><aff id="AF1"><label>a</label><institution>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University</institution>, Xiamen, <country>PR People&#x02019;s Republic of China</country></aff><aff id="AF2"><label>b</label><institution>Department of Microbiology, Howard University College of Medicine</institution>, Washington, DC, <country>USA</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Tong Cheng <email xlink:href="tcheng@xmu.edu.cn">tcheng@xmu.edu.cn</email></corresp><corresp id="cor2">Ningshao Xia <email xlink:href="nsxia@xmu.edu.cn">nsxia@xmu.edu.cn</email><institution>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University</institution>, Xiamen 361102, <country>PR People&#x02019;s Republic of China</country></corresp><fn id="an1"><label>*</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>13</day><month>5</month><year>2020</year></pub-date><volume>9</volume><issue>1</issue><fpage seq="109">949</fpage><lpage>961</lpage><history><date date-type="received"><day>18</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>22</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TEMI_9_1764871.pdf"/><abstract><title>ABSTRACT</title><p>The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (17 April 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Coronavirus</kwd><kwd>infectious disease</kwd><kwd>respiratory syndrome</kwd><kwd>animal model</kwd><kwd>vaccine and drug discovery</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">National Science and Technology Major Projects for Major New Drugs Innovation and Development</named-content></funding-source><award-id>2018ZX09711003-005-003</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">National Science and Technology Major Project of Infectious Diseases</named-content></funding-source><award-id>2017ZX10304402</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Key Research Program of the Ministry of Science and Technology</named-content></funding-source><award-id>2020YFC0842600</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Science and technology project of Fujian Province</named-content><named-content content-type="funder-identifier">10.13039/501100005270</named-content></funding-source><award-id>2020YZ0106</award-id></award-group><funding-statement>This work was supported by the National Science and Technology Major Projects for Major New Drugs Innovation and Development (No. 2018ZX09711003-005-003), the National Science and Technology Major Project of Infectious Diseases (No. 2017ZX10304402), Key Research Program of the Ministry of Science and Technology (2020YFC0842600) and the Science and technology project of Fujian Province (2020YZ0106).</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="79"/><page-count count="13"/></counts></article-meta></front><body><sec id="S001"><title>Introduction</title><p>The pleomorphic and enveloped coronaviruses are a genus in the <italic>Coronaviridae</italic> family and contain a &#x0223c;30&#x02005;Kb positive-sense RNA genome [<xref rid="CIT0001" ref-type="bibr">1</xref>]. The viral envelop contains envelope (E) protein, transmembrane (M) and spike (S) glycoprotein, and surrounds a disordered or flexible nucleocapsid (N) [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Most coronaviruses infect wild animals with narrow host range and cause self-limiting diseases [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Human coronaviruses such as OC43, 229E, NL63 and HKU1 are associated with self-limiting respiratory tract infections [<xref rid="CIT0003" ref-type="bibr">3</xref>]. However, two zoonotic coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV), cross the species barrier to infect humans and have caused severe acute respiratory disease (SARD) and thousands of deaths [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>]. Since December of 2019, a new &#x0201c;SARS-like&#x0201d; coronavirus, named SARS-CoV-2, raised intense concerns not only within China but also internationally [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Importantly, SARS-CoV-2 showed approximately 80&#x0223c;90% of genome sequence homology with previously identified SARS-CoV strains, suggesting an evolving similarity in virological properties [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>Receptor-mediated entry is the first step of a viral infection in the host cell. Receptor binding domain (RBD) of the viral S protein of SARS-CoV or MERS-CoV attaches to human angiotensin converting enzyme 2 (hACE2) or dipeptidyl peptidase 4 (hDPP4) proteins, respectively. The hACE2 has been also believed to be the receptor of SARS-CoV-2 [<xref rid="CIT0007" ref-type="bibr">7</xref>]. After entry into cells, these three coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) replicate efficiently to produce progeny viruses, give rise to cytopathogenesis and establish productive infection. SARS-CoV of 2002 caused over 8098 cases and 774 deaths in over 30 countries. MERS-CoV of 2012 resulted in more than 2182 cases and 779 deaths in 27 countries. SARS-CoV-2 has caused over two million cases in more than 213 countries, areas or territories with over 150,000 deaths up to date (17 April 2020). Therefore, it is highly emergent to obtain the effective clinical medication and vaccines to prevent and treat coronavirus infection.</p><p>Animal models are critical for us to understand the viral infection and pathogenesis. Moreover, animal models are essential for development and preclinical evaluation of a vaccine or an antiviral agent. An ideal animal model is the one that mimics viral infection and diseases in humans in multiple aspects including morbidity, viral load, typical clinical symptoms, host immune responses and mortality. Therefore, the urgent need of preventing and controlling coronavirus infection necessitates the search for an optimal SARS-CoV-2 animal model. Based on the published studies, animal models of SARS-CoV and MERS-CoV include civet cats, camelidaes, monkeys, mice, hamsters, ferrets, rabbits and other potential hosts (<xref rid="F0001" ref-type="fig">Figure 1</xref>). We aim to summarize and discuss their ability to mimic the disease symptoms and natural history of coronavirus disease 19 (COVID-19) in humans, as well as their usage in development of vaccine and antiviral drugs. Furthermore, humanized animal models available to support coronavirus infection and pathogenesis might provide new options to overcome the limitations of the traditional coronavirus animal models. Additionally, animal models for pseudovirus are also prospected to avoid the concern of biosafety.
<fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Experimental animals of SARS-CoV, MERS-CoV and SARS-CoV-2. The coronaviruses with high infectivity and pathogenicity break the species barrier and infect human in the past two decades. Besides NHP, mice, hamsters, ferrets and rabbits, the other possible natural hosts might be able to support the studies of coronavirus infection, pathogenesis and drug discovery.</p></caption><graphic xlink:href="TEMI_A_1764871_F0001_OC"/></fig></p></sec><sec id="S002"><title>Emerging coronaviruses infection in humans</title><p>Clinical symptoms of SARS-CoV- and MERS-CoV-infected patients at early time include fever, chills, coughing, malaise, myalgia, headache, diarrhoea, vomiting and nausea [<xref rid="CIT0008" ref-type="bibr">8</xref>]. Furthermore, immunohistochemistry (IHC) detection demonstrated the presence of viral antigens in lung tissues. The COVID-19 patients present similar symptoms to those of SARS-CoV- or MERS-CoV-infected patients, while some patients may show no typical clinical symptom in the early stage of infection [<xref rid="CIT0009" ref-type="bibr">9</xref>]. The typical pathological features of severe cases include prolonged inflammation with destruction and desquamation of alveolar pneumocytes, hyaline-membrane formation, interstitial inflammatory infiltration and interalveolar hemorrhage. Multinucleated giant cells were also observed in the tissues of COVID-19 patients [<xref rid="CIT0010" ref-type="bibr">10</xref>]. Over 70% of COVID-19 patients were diagnosed as pneumonia by chest computed tomography (CT) to be admitted to hospital. CT images showed the typical features of ground-glass opacity and bilateral patchy shadowing in lungs [<xref rid="CIT0009" ref-type="bibr">9</xref>]. Recent clinical and experimental studies have demonstrated SARS-COV-2 caused the nosocomial infection and fecal-oral transmission, its infection results in immune abnormality and multiple organ failures of the COVID-19 patients. Moreover, a long incubation period (&#x0003e;29 days) was observed in some COVID-19 cases [<xref rid="CIT0011" ref-type="bibr">11</xref>], suggesting a risk of occult and chronic infection. Although SARS-COV-2 displays a lower rate of severe cases and case fatality than SARS-CoV and MERS-CoV, its high infectivity, widely spreading and huge infection population have become a catastrophic medical burden and critical social problem.</p></sec><sec id="S003"><title>Natural infectious animal models</title><p>Viral entry and intracellular replication are two essential steps for a virus to establish a successful infection. The specific receptor proteins anchored on cell membrane mediate viral entry and intranuclear transcriptional factors regulate viral replication. Therefore, host-range of virus depends on these two steps. As summarized in <xref rid="T0001" ref-type="table">Table 1</xref>, non-human primates (NHPs), ferrets and hamsters have been demonstrated to support SARS-CoV infection and pathogenesis, but only the NHPs are fully permissive for MERS-CoV infection. The civet cats were demonstrated permissive for SARS-CoV infection by serological antibody detection. The camelidaes have been demonstrated permissive for MERS-CoV infection because the specific antibodies against MERS-CoV S protein were detected at a high rate, and respiratory infections after the administration of MERS-CoV. Immunocompetent young inbred mice support transient SARS-CoV infection without clinical signs of disease [<xref rid="CIT0012" ref-type="bibr">12</xref>], but were not permissive to MERS-CoV due to the lack of functional receptor [<xref rid="CIT0013" ref-type="bibr">13</xref>]. After a careful review of their illness, virological, histological and immunological characteristics post infection, NHPs, ferrets and hamsters have been presumed to be potential natural hosts of SARS-CoV-2. Meanwhile, other experimental animal models such as tree shrew, woodchuck, pangolin, rat, guinea pig and cotton mouse, as well as domesticated animals such as cats [<xref rid="CIT0014" ref-type="bibr">14</xref>] and dogs might be potential hosts to support SARS-CoV-2 infection.
<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Natural infectious animal model for SARS-CoV and MERS-CoV.</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead valign="bottom"><tr><th align="left">Animals</th><th align="center">SARS-CoV</th><th align="center">MERS-CoV</th></tr></thead><tbody><tr><td align="left">NHPs</td><td align="left">Rhesus and cynomolgus macaques, African green monkeys, common marmosets, squirrel monkeys and mustached tamarins; clinical signs, viral replication and pathology degree varied on the species</td><td align="left">Common marmosets have a more severe response to the virus with higher viral titres and severe pathology than rhesus macaques; lethality is only observed in common marmosets</td></tr><tr><td align="left">Mice</td><td align="left">Immunocompetent young inbred mice support transient infection without clinical illness</td><td align="left">Not permissive for entry</td></tr><tr><td align="left">Hamsters</td><td rowspan="2" align="left">Self-limiting infection; mild clinical illness</td><td rowspan="2" align="left">Not permissive for viral replication</td></tr><tr><td align="left">Ferrets</td></tr><tr><td align="left">Civet cats</td><td align="left">Permissive to infection and replication; mild clinical illness</td><td align="left">No report</td></tr><tr><td align="left">Rabbits</td><td align="left">No report</td><td align="left">Infection with mild clinical illness</td></tr><tr><td align="left">Camelidae</td><td align="left">No report</td><td align="left">Infection without clinical illness</td></tr></tbody></table></table-wrap></p><sec id="S003-S2001"><title>The NHPs</title><p>The studies of coronavirus have been greatly benefited from the using NHPs as the infection and disease models. The old- and new-world monkeys include rhesus macaques <italic>(Macaca mulatta)</italic>, cynomolgus macaques <italic>(Macaca fascicularis)</italic>, African green monkeys <italic>(Chlorocebus sabaeus)</italic>, common marmosets <italic>(Callithrix jacchus)</italic>, squirrel monkeys <italic>(Saimiri)</italic>, and mustached tamarins <italic>(Saguinus mystax)</italic>, all of them have been demonstrated to be permissive for SARS-CoV infection to cause symptoms such as fever, diarrhea and clinical manifestations of pneumonitis [<xref rid="CIT0015" ref-type="bibr">15</xref>,<xref rid="CIT0016" ref-type="bibr">16</xref>]. The African green monkeys, cynomolgus and rhesus macaques showed mild symptoms after infection of SARS-CoV Urbani strain and they produced neutralizing antibodies (NAbs) that might help to clear the virus [<xref rid="CIT0017" ref-type="bibr">17</xref>]. In another study on rhesus macaques challenged with the SARS-CoV PUMC01 strain, transient severe pneumonia was observed [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Meanwhile, Greenough et al. reported SARD with fever, diarrhea, hepatitis and multi-organ failure in common marmosets around four to seven days post SARS-CoV infection [<xref rid="CIT0019" ref-type="bibr">19</xref>].</p><p>In some studies, the rhesus macaques and common marmosets were used as a model for MERS-CoV infection. However, MERS-CoV infections in the two NHPs caused different levels of consequences. First, the symptoms in the common marmoset model was much more severe and viral yield was approximately thousand-fold higher than those in the rhesus macaque model. Secondly, viral replication in the common marmosets reached peak level and the viral infection caused severe pneumonia within four to six days post MERS-CoV infection [<xref rid="CIT0020" ref-type="bibr">20</xref>]. However, MERS-CoV infection in the rhesus macaques did not produce a high viral load and didn't cause severe symptoms [<xref rid="CIT0021" ref-type="bibr">21</xref>]. The rhesus macaque has been demonstrated permissive for SARS-CoV-2 infection via ocular conjunctival route [<xref rid="CIT0022" ref-type="bibr">22</xref>]. SARS-CoV-2 induced a transient infection and mild pneumonia in the rhesus macaques. However, severe pneumonia and death were not observed. Meanwhile, the infected rhesus macaques pounced NAbs that effectively prevent re-challenge of SARS-CoV-2 [<xref rid="CIT0023" ref-type="bibr">23</xref>]. More recently, the cynomolgus macaques and common marmosets were also demonstrated available to support SARS-CoV-2 infection [<xref rid="CIT0024" ref-type="bibr">24</xref>]. In this study, rhesus macaques were demonstrated more susceptible to SARS-CoV2 infection as compared to cynomolgus macaques and common marmosets.</p></sec><sec id="S003-S2002"><title>Ferrets, hamsters and rabbits</title><p>Ferrets has been used as a model for the studies of respiratory pathogens including influenza virus (IFV), respiratory syncytial virus (RSV), adenovirus and coronavirus. Up on infection of SARS-CoV, the ferret presented fever and sneezing associated with detectable viral titres in the upper respiratory tract [<xref rid="CIT0025" ref-type="bibr">25</xref>]. However, severe symptoms and deaths caused by viral infection were not observed, and ferrets do not support replication of MERS-CoV [<xref rid="CIT0026" ref-type="bibr">26</xref>]. Recently, ferrets were demonstrated available to support SARS-CoV-2 infection by two different groups [<xref rid="CIT0014" ref-type="bibr">14</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref>]. It was reported that SARS-CoV infects the golden Syrian hamster [<xref rid="CIT0028" ref-type="bibr">28</xref>]. Viruses seeded in the upper and lower respiratory tract and reached a peak level at three days post SARS-CoV infection and declined and cleared within seven to ten days. The infection of SARS-CoV resulted in mild and transient pneumonia. By contrast, similar infection course and symptoms were recently observed in hamsters that infected with SARS-CoV-2 [<xref rid="CIT0029" ref-type="bibr">29</xref>]. Hamsters have been demonstrated not susceptible to MERS-CoV infection [<xref rid="CIT0028" ref-type="bibr">28</xref>]. Interestingly, primary SARS-CoV and SARS-CoV-2 infection in ferrets and hamsters elicited a strong NAb response that protected the hosts from subsequent infections. The above-mentioned information implies that SARS-CoV-2 infection might induce a mild to severe pulmonary diseases in ferrets and hamsters. The severities of symptom might depend on viral strains. The ability of MERS-CoV to infect small animal species may be defected by lack of viral entry or replication. Surprisingly, rabbits were susceptible to MERS-CoV infection [<xref rid="CIT0030" ref-type="bibr">30</xref>]. Although viral nucleic acid and infectious progeny virus were detectable in lung tissues, neither significant histopathological changes nor clinical symptoms were observed. These findings indicate a potential route of MERS-CoV transmission in some common animal species. However, there is no reported investigation of SARS-CoV and SARS-CoV-2 infection in the rabbits. Therefore, it is important to experimentally investigate whether ferret, hamster and rabbit are susceptible to the infection and are able to be used as animal model of SARS-CoV-2.</p></sec></sec><sec id="S004"><title>Mouse models</title><p>Mouse model has been widely used for many different viral investigations. It has been considered as the best small animal model for hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), Zika virus, and among others. Due to its low cost, small size, easy operation and high reproducibility, mouse model is suitable for large scale studies of viruses not only for the pathogenesis but also for antivirals. In contrast of the NHPs, mice are more convenient to be handled in a higher level of biosafety laboratory due to its relatively small size and less operation difficulties. Importantly, mouse can be easily manipulated at the genetic level for precision research. For instance, a lot of genetically mutated mice are available for studies in anti-viral immunity, viral pathogenesis and viral infection and transmission restriction. Furthermore, current murine immunological reagents are available to study viral pathogenesis and host immune responses.</p><sec id="S004-S2001"><title>Mouse expressing human receptor</title><p>Several strains of mice have been tried to be intranasally infected with SARS-CoV (Urbani strain), it was found that the virus poorly replicated in several young and adult inbred strains of mice (BALB/c, C57BL6 and 129S) to only a low viral yield. Clinical illness was not observed, and the virus was cleared within nine days. Meanwhile, mice are not naturally susceptible to MERS-CoV infection. It was later revealed that the mouse DPP4 receptor differs from human counterpart in crucial domains that is critical to bind the S protein [<xref rid="CIT0013" ref-type="bibr">13</xref>]. To overcome the species-specificity barrier for SARS-CoV or MERS-CoV, human receptor protein (hACE2 or hDPP4) was expressed in mice by knocking in or transfecting a human receptor gene in mouse. The studies of hACE2-transgenic mice were performed at almost the same time in 2007 independently in three groups. They reported that hACE2-transgenic mice supported SARS-CoV infection and pathogenesis. McCray et al. demonstrated that systemic expression of hACE2 under the control of an epithelial cell-specific promoter K18 resulted in lethal SARS-CoV infection within five days [<xref rid="CIT0031" ref-type="bibr">31</xref>]. Tseng et al. developed two lineages of transgenic mice expressing hACE2 under the CAG promoter [<xref rid="CIT0032" ref-type="bibr">32</xref>]. After SARS-CoV infection, the two transgene-positive mice, AC70 and AC63 showed high viral load, clinical illness and tissue pathology. The lethal lineage of mice (AC70) displayed higher hACE2 expressions in several organs, wider spectrum of clinical illness, including wasting symptom, severe pneumonia and death, rather than the non-lethal lineage mice (AC63) with lower hACE2 expressions. Yang et al. generated another non-lethal lineage mouse that expresses hACE2 under mouse ACE2 promoter [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Another study further revealed the differential virological and immunological outcomes among different hACE2 transgenic lineages [<xref rid="CIT0034" ref-type="bibr">34</xref>].</p><p>To rapidly generate a MERS-CoV infecting mouse model, Zhao et al. transduced common adult BALB/c and C57BL6 mice with an adenoviral vector expressing hDPP4 (Ad5-hDPP4). After MERS-CoV infection, these mice showed interstitial pneumonia, expressed viral antigen in the lungs and lost weight, but deaths were not observed. Later, hDPP4-transgenic mice were generated to mimic severe MERS-CoV infection and lethal pathogenesis. Agrawal et al. developed a transgenic mouse that expresses hDPP4 under the control of the CAG promoter [<xref rid="CIT0035" ref-type="bibr">35</xref>]. This hDPP4-transgenic mouse was fully permissive for MERS-CoV infection to cause severe respiratory illness that led to death within six days after infection. Remarkably, high viral load was detected in multiple organs and pathological changes were consistent with extensive inflammation throughout the infection course. In addition, MERS-CoV infection induced profound acute innate inflammatory responses within the lungs of this model. In 2017, Li et al. developed another hDPP4-transgenic mouse and demonstrated that MERS-CoV infection induced lethal lung disease is viral load dependent [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Similar to the model by Agrawal et al., activated innate immune cells accumulated in the lungs after MERS-CoV infection. Recently, Yoshikawa et al. observed the cytokine storm in a newly generated hDPP4-transgenic mouse [<xref rid="CIT0037" ref-type="bibr">37</xref>].</p><p>These receptor-transgenic or -transduced mice have been widely used to study the pathogenesis mechanism and evaluate vaccines and other therapeutics (<xref rid="T0002" ref-type="table">Table 2</xref>). Because hACE2 has been recently demonstrated as the receptor of SARS-CoV-2 in a cell infectious model [<xref rid="CIT0007" ref-type="bibr">7</xref>], the hACE2 transgenic mice are supposed as an option to study SARS-CoV-2 infection and pathogenesis. Recently, Bao et al demonstrated that hACE2-transgenic mice are able to support SARS-CoV-2 infection [<xref rid="CIT0038" ref-type="bibr">38</xref>]. It is observed that mice presented weight loss, virus replication, infiltration of lymphocytes and monocytes in alveolar interstitium and accumulation of macrophages in alveolar cavities from three to five days post SARS-CoV-2 infection. However, no significant histopathological lesions or viral antigens were observed in the other organs, including myocardium, liver, spleen, kidney, cerebrum, intestine, and testis. Furthermore, pneumonia became mild with focal lesion areas at seven days post infection, suggesting a non-lethal and self-limiting infection course. This lineage of hACE2-transgenic mouse cannot mimic the severe and lethal cases of COVID-19, which necessity attempts in other lineages with different hACE2 promotors. Alternatively, transduction of Ad-hACE2 in young adult BALB/c and C57BL6 mice might provide an avenue for rapid and robust generation of SARS-CoV-2 infectious mouse model.
<table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Representative receptor transgenic and transfected mice support SARS-CoV and MERS-CoV infection.</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead valign="bottom"><tr><th rowspan="2" align="left">&#x000a0;</th><th colspan="2" align="center">SARS-CoV</th><th colspan="4" align="center">MERS-CoV</th></tr><tr><th align="center">McCray et al. [<xref rid="CIT0031" ref-type="bibr">31</xref>]</th><th align="center">Tseng et al. [<xref rid="CIT0032" ref-type="bibr">32</xref>]</th><th align="center">Zhao et al. 2014</th><th align="center">Agrawal et al. [<xref rid="CIT0035" ref-type="bibr">35</xref>]</th><th align="center">Li et al. [<xref rid="CIT0036" ref-type="bibr">36</xref>]</th><th align="center">Iwata-Yoshikawa et al. [<xref rid="CIT0037" ref-type="bibr">37</xref>]</th></tr></thead><tbody><tr><td align="left">Background</td><td colspan="2" align="center">C57BL6</td><td align="left">C57BL6; BALB/c</td><td colspan="2" align="center">C57BL6</td><td align="left">BDF1&#x02009;&#x000d7;&#x02009;C57BL6</td></tr><tr><td align="left">Age (weeks)</td><td align="left">&#x000a0;6&#x0223c;8</td><td align="left">8&#x0223c;20</td><td align="left">6&#x0223c;22</td><td align="left">5&#x0223c;7</td><td align="left">6&#x0223c;13</td><td align="left">9&#x0223c;25</td></tr><tr><td align="left">Viral strains</td><td colspan="2" align="center">Urbani</td><td align="left">EMC/2012; EMC/Vero; MERS<sub>MA</sub></td><td align="left">EMC/2012; rMERS-CoV/RFP</td><td align="left">EMC/2012; EMC/Vero; MERS<sub>MA</sub></td><td align="left">EMC/2012;</td></tr><tr><td align="left">Inoculation dose</td><td align="left">2.3&#x02009;&#x000d7;&#x02009;10<sup>5</sup> PFU</td><td align="left">2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> TCID<sub>50</sub></td><td align="left">1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> PFU</td><td align="left">1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> TCID<sub>50</sub></td><td align="left">50&#x0223c;5000 PFU</td><td align="left">1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> TCID<sub>50</sub></td></tr><tr><td align="left">Clinical illness</td><td colspan="2" align="left">Severe pneumonia; weight loss; robust cytokine storm in lung and brain</td><td align="left">Mild inflammatory cell infiltrates; weight loss</td><td align="left">Severe pneumonia; weight loss; robust cytokine storm in lung and brain</td><td align="left">Viral strain dependent; mild to severe pneumonia; weight loss; activation of innate immune cells</td><td align="left">Mild pneumonia; weight loss; slight cytokine storm in lung and brain</td></tr><tr><td align="left">Peak viral load</td><td align="left">&#x0223c;10<sup>8</sup> TCID<sub>50</sub>/g in lung at 4dpi</td><td align="left">&#x0223c;10<sup>9</sup> TCID<sub>50</sub>/g in lung and brain at 4dpi</td><td align="left">&#x0223c;10<sup>7</sup> PFU/g in lung at 2&#x0223c;3dpi</td><td align="left">&#x0223c;10<sup>8</sup> TCID<sub>50</sub>/g in lung at 2dpi; &#x0223c;10<sup>5</sup> TCID<sub>50</sub>/g in brain at 4dpi;</td><td align="left">Viral strain dependent; &#x0223c;10<sup>8</sup> PFU/g in lung at 1&#x0223c;3dpi (5000 PFU of MERS<sub>MA</sub>)</td><td align="left">&#x0223c;10<sup>5</sup> TCID<sub>50</sub>/g in lung at 3dpi</td></tr><tr><td align="left">Mortality rate</td><td align="left">&#x0223c;90% at 4 dpi</td><td align="left">AC63 (None); AC70 (100% at 8 dpi)</td><td align="left">None</td><td align="left">100% at 6 dpi</td><td align="left">Viral strain and inoculated dose dependent; 100% at 6 dpi (5000 PFU of MERS<sub>MA</sub>)</td><td align="left">None</td></tr></tbody></table></table-wrap></p></sec><sec id="S004-S2002"><title>Adapting human coronavirus to mouse</title><p>In order to promote the replication of SARS-CoV in young adult immunocompetent mouse, three mouse-adapted (MA) viral strains were developed by serial passage of SARS-CoV (Urbani strain) in mouse respiratory tract. In contrast to the original Urbani strain, the SARS-CoV MA (SARS<sub>MA</sub>) strains such as MA15, MA20 and v2163 replicated in the lungs of mice to a higher titre that is proportionally associated with pathological changes, dissemination of the virus to extrapulmonary sites and mortality (<xref rid="T0003" ref-type="table">Table 3</xref>). As shown in <xref rid="F0002" ref-type="fig">Figure 2</xref>A, several mutations occurred in ORF1a (nsp5 and nsp9), ORF1b (nsp13), and S protein. It is believed that the combination of these genetic changes enhanced the viral virulence [<xref rid="CIT0039" ref-type="bibr">39</xref>], implying the importance of these proteins in viral pathogenesis. In brief, the three SARS<sub>MA</sub> strains induced SARD in mice that is similar to the clinical symptoms observed in human cases of SARS-CoV infection.
<fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Mutations in MA stains of SARS-CoV and MERS-CoV. (A) Nucleic acid and amino acid mutations of SARS<sub>MA</sub> strain MA15, MA20, and v2163 [<xref rid="CIT0039" ref-type="bibr">39</xref>]. (B) Amino acid changes of MERS-CoV S1 (receptor binding) and S2 (fusion) domains of different plaques and clones of the EMC-P30 strain [<xref rid="CIT0036" ref-type="bibr">36</xref>].</p></caption><graphic xlink:href="TEMI_A_1764871_F0002_OC"/></fig>
<table-wrap id="T0003" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Infection outcomes of mouse-adapted SARS-CoV strains.</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead valign="bottom"><tr><th align="left">Strains</th><th align="center">Urbani (wt)</th><th align="center">Urbani<sub>+S</sub></th><th align="center">Urbani<sub>+N9</sub></th><th align="center">Urbani<sub>+N9/S</sub></th><th align="center">MA15</th><th align="center">MA<sub>+N9/S</sub></th><th align="center">MA20</th><th align="center">v2163</th><th align="center">Urbani</th><th align="center">MA15</th></tr><tr><th align="left">Mouse</th><th colspan="6" align="center">One-year-old BALB/c</th><th colspan="4" align="center">5&#x0223c;10 week BALB/c</th></tr></thead><tbody><tr><td align="left">Inoculation dose</td><td colspan="8" align="center">1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> PFU</td><td colspan="2" align="left">1&#x02009;&#x000d7;&#x02009;10<sup>5.5</sup> CCID<sub>50</sub></td></tr><tr><td align="left">Peak viral load in lung at 2&#x0223c;4 dpi</td><td align="left">&#x0223c;10<sup>5</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>7.2</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>8</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>7.5</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>6</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>6.5</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>6.5</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>7.5</sup><break/>PFU/g</td><td align="left">&#x0223c;10<sup>5.8</sup> CCID<sub>50</sub>/g</td><td align="left">&#x0223c;10<sup>6.6</sup><break/>CCID<sub>50</sub>/g</td></tr><tr><td align="left">Mortality rate</td><td align="left">None</td><td align="left">100% at 8dpi</td><td align="left">None</td><td align="left">100% at 4dpi</td><td align="left">100% at 5dpi</td><td align="left">100% at 4dpi</td><td align="left">&#x000a0;ND</td><td align="left">100% at 6dpi</td><td align="left">None</td><td align="left">90% at10 dpi</td></tr><tr><td align="left">Mean day of death (days)</td><td align="center">&#x02013;</td><td align="left">6.0&#x02009;&#x000b1;&#x02009;1.26</td><td align="center">&#x02013;</td><td align="left">3.2&#x02009;&#x000b1;&#x02009;0.44</td><td align="left">3.8&#x02009;&#x000b1;&#x02009;1.09</td><td align="left">3.2&#x02009;&#x000b1;&#x02009;0.40</td><td align="left">&#x000a0;ND</td><td align="left">4.8&#x02009;&#x000b1;&#x02009;1.8</td><td align="center">&#x02013;</td><td align="left">6.8&#x02009;&#x000b1;&#x02009;1.4</td></tr><tr><td align="left">LD<sub>50</sub></td><td align="center">&#x02013;</td><td align="left">10E4.4</td><td align="center">&#x02013;</td><td align="left">10E2.5</td><td align="left">&#x0003c;10E2</td><td align="left">10E2.3</td><td align="left">&#x000a0;ND</td><td align="left">10E3.3</td><td align="center">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table></table-wrap></p><p>Ferrets, hamsters and mice are not naturally susceptible to MERS-CoV infection, because MERS-CoV S protein cannot bind DPP4 of these animals. Thus, progeny infectious virus could not be isolated from these animals after initial infection, and the MERS-CoV adaptation is unlikely to be carried out. As mentioned above, MERS-CoV can successfully infect a hDPP4-transgenic mouse. Interestingly, <italic>in vivo</italic> serial passage of the EMC/2012 strain of MERS-CoV in the hDPP4 knock-in mice resulted in a MA virus strain (MERS<sub>MA</sub>) that causes a fatal pulmonary disease phenotype associated with severe inflammatory responses [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Furthermore, it was reported that more passages in the mouse caused more severe diseases. For example, the MERS<sub>MA</sub> strain with 21 adaptive passages (EMC-P21) cause 50% lethality of hDPP4 transgenic mice, while the strain with 30 adaptive passages (EMC-P30) killed all the mice within eight days [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Moreover, different mutations in MERS-CoV S1 (receptor binding domain) and S2 (fusion domain) occur in different plaques or clones of the passaged EMC-P30 strain, implying that the gene diversity has impacts on the viral entry (<xref rid="F0002" ref-type="fig">Figure 2</xref>B).</p><p>The S protein of coronaviruses needs to be cleaved by host proteases to be functional. The proteases include endosomal cathepsins, cell surface transmembrane protease/serine (TMPRSS) proteases, furin, and trypsin [<xref rid="CIT0040" ref-type="bibr">40</xref>]. For example, SARS-CoV-2 uses serine protease, TMPRSS2 in host cell to cleave S protein to activate its entry process [<xref rid="CIT0041" ref-type="bibr">41</xref>]. The S protein mutations enhanced infectivity of MERS<sub>MA</sub> strains by promoting early entry and broadening tissue tropism [<xref rid="CIT0042" ref-type="bibr">42</xref>]. Comparing to MERS strain with an uncleaved S protein, MERS<sub>MA</sub> strain has an S protein that is pre-cleaved by furin of the infected cells and hence achieves a non-endosome cellular entry. Thus, mutations in the protease cleaving site of S protein might alter infectivity of SARS-CoV-2. Considering the similarity of receptor and highly gene sequence homology between SARS-CoV and SARS-CoV-2, adaptive viral strain of the novel coronavirus might be obtained after 10&#x0223c;20 serial passage in hACE2 transfected cells or animal models. Overall, generating adaptive viral strains might become another approach to enhance the infectivity and establish an effective and lethal SARS-CoV-2 infection in experimental animals.</p></sec><sec id="S004-S2003"><title>Immunodeficient mouse</title><p>Several studies have attempted to use the immune-compromised mice to determine the role of immune effectors in the coronavirus infection. First, the following knock-out mice have been applied for the infection of SARS-CoV: beige lacking functional NK cells, CD1<sup>&#x02212;/&#x02212;</sup> lacking NK-T cells, Rag<sup>&#x02212;/&#x02212;</sup> lacking T and B cells [<xref rid="CIT0043" ref-type="bibr">43</xref>]. However, all the immune-compromised mice failed to allow the infection of SARS-CoV. Viral kinetics were not significantly different among the 57BL6 (wild type), beige, CD1<sup>&#x02212;/&#x02212;</sup> and Rag1<sup>&#x02212;/&#x02212;</sup> mice. Histopathological detection showed similar self-limiting bronchiolitis and mild pneumonia among these mice. Interestingly, a prolonged viral replication and illness were observed in STAT1<sup>&#x02212;/&#x02212;</sup> mice with 129S background [<xref rid="CIT0044" ref-type="bibr">44</xref>]. In this model, viral replication is detectable until day 22 post infection indicating that a STAT1 mediated type I interferon response is required to control SARS-CoV infection [<xref rid="CIT0045" ref-type="bibr">45</xref>]. The STAT1<sup>&#x02212;/&#x02212;</sup> mice were also challenged with MERS-CoV (EMC-2012 strain). Because the lack of receptor hDPP4, clinical illness were not observed and viral replication was undetectable [<xref rid="CIT0046" ref-type="bibr">46</xref>]. However, the hDPP4-transfected mice additional deficiency of interferon-&#x003b1; receptor, MyD88 and MVAS still cannot prolong the viral replication or cause severe cause throughout a MERS-CoV infection course [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Generally, mice with targeted immune deficiency are useful tools to investigate interaction between host immunity and coronavirus. Besides the relatively low viral load and mild illness, the immunodeficient mice are of limited value in the studies of vaccine and immunotherapy.</p></sec><sec id="S004-S2004"><title>Host factors impact on coronavirus infection</title><p>It is important to know the risk factors that affect the clinical outcomes of coronavirus infection [<xref rid="CIT0047" ref-type="bibr">47</xref>]. First, does age play an important role in disease severity? To know that, an aged mouse model was used for SARS-CoV infection and it was found that SARS-CoV infection in aged mice resulted in increased mortality than that in younger mice. In the studies, 12&#x02013;14 month old BALB/c or C57BL6 mice developed more severe disease include viral replication, weight loss, ruffled fur and dehydration than that in the 6&#x0223c;12 week-old ones [<xref rid="CIT0048" ref-type="bibr">48</xref>]. However, aged 129SvEv mice did not support prolonged pulmonary viral replication and cleared the virus within five days [<xref rid="CIT0049" ref-type="bibr">49</xref>]. Interestingly, the SARS<sub>MA</sub> strain MA15 showed higher mortality in the 9&#x0223c;20 month aged BALB/c and C57BL6 mice than that in the 2&#x0223c;5 month ones [<xref rid="CIT0050" ref-type="bibr">50</xref>]. Recently, Yoshikawa et al. demonstrated that the immunopathology degree of MERS-CoV infection in the hDPP4-transgenic mouse is age dependent [<xref rid="CIT0037" ref-type="bibr">37</xref>]. Mechanistic studies demonstrated that age-dependent increases of phospholipase PLA<sub>2</sub>G2D and dysfunction of CD4 positive T cell could be the reasons for the enhanced SARS-CoV infection [<xref rid="CIT0051" ref-type="bibr">51</xref>,<xref rid="CIT0052" ref-type="bibr">52</xref>]. According to epidemiology data, SARS-CoV-2 is more likely to cause severe causes and high mortality in elder people [<xref rid="CIT0053" ref-type="bibr">53</xref>]. Overall, the aged mouse model provided an opportunity to study the age-dependent susceptibility of humans to coronavirus.</p><p>Second, does the gender has impact on infection outcomes? Generally, the males generate mild immune responses and females mount stronger innate and adaptive immune responses and are relatively resistant to virus infections, which explains why males and females showed different response patterns after infection of viruses. Recent studies showed the higher expression of hACE2 in Asian males than the females [<xref rid="CIT0054" ref-type="bibr">54</xref>]. Epidemiological data showed gender-specific differences in SARS-CoV infection with males experiencing higher mortality compared to females [<xref rid="CIT0055" ref-type="bibr">55</xref>]. This gender-dependent increase in disease severity after pathogenic SARS-CoV infection was more pronounced with advancing age [<xref rid="CIT0055" ref-type="bibr">55</xref>]. Male C57BL6 and BALB/c mice showed more susceptible to and higher mortality after SARS-CoV MA15 infection than female mice [<xref rid="CIT0050" ref-type="bibr">50</xref>]. In addition, the male mice displayed a higher proinflammatory cytokine levels than female ones, which was is independent of T and B cell responses throughout the SARS-CoV infection course. These clinical and experimental findings imply a higher risk of SARS-CoV and SARS-CoV-2 infection in the elder Asian males. However, MERS-CoV infection showed no difference between male and female hDPP4-transgenic mice in mortality and weight loss. The epidemiological data of MERS-CoV infection in human with different gender is conflict. Some study showed high incidence and mortality among the males [<xref rid="CIT0056" ref-type="bibr">56</xref>], and others showed that gender may not have impact on the infection outcome of MERS-CoV [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Thus, it is necessary to clarify the conflicting results of gender impacts in clinical and experimental studies of MERS-CoV infection. Overall, gender might be an interesting topic for further investigation for the mechanism of SARS-CoV-2 infection and pathogenesis. In addition, infection routes and inoculation doses might also have impact on the characteristics of virus shedding, pathogenesis and disease outcomes in experimental animals.</p><p>Presumptively, animal models of SARS-CoV might fit for the study of SARS-CoV-2 due to the similarities of the two viruses in pathogenesis, replication, viral characteristics and host receptor for viral entry. Therefore, combination of hACE2 transgenic- or transduce-mice and SARS-CoV-2 MA strains might result in an enhanced infection, severe pathogenesis and higher mortality, which resembling the clinical illness. Comparing to SARS-CoV and MERS-CoV, the SARS-CoV-2 might be more complicated in transmission and pathogenesis, which makes the animal studies more difficult. For example, SARS-CoV-2 infection has a long incubation time [<xref rid="CIT0011" ref-type="bibr">11</xref>], more rapid transmission among populations [<xref rid="CIT0053" ref-type="bibr">53</xref>] and more severe multiple organ failure [<xref rid="CIT0047" ref-type="bibr">47</xref>].</p></sec></sec><sec id="S005"><title>Coronavirus vaccine candidates evaluated in animal models</title><p>An appropriate animal model is important to evaluate a vaccine in medical safety, protective efficacy and comprehensive immune activation. Although many attempts of developing vaccines have been tried, there is currently no approved vaccine for SARS-CoV and MERS-CoV. Several approaches to develop SARS-CoV and MERS-CoV vaccines were evaluated in indicated animal models that are summarized in <xref rid="T0004" ref-type="table">Table 4</xref>. The traditional inactivated virus vaccines use chemicals or radiation to render the viral genome non-infectious while maintaining the virion structure, thus preserving antigenicity but eliminating the potential to cause productive infection. Animal studies have assessed the inactivated SARS-CoV vaccines and found that they can elicit the production of NAbs and inhibit viral replication in NHPs, mice, ferrets and hamsters. However, in some cases, the inactivated vaccine may not arouse enough NAbs for the cover or damage of dominant epitopes [<xref rid="CIT0057" ref-type="bibr">57</xref>]. Moreover, the inactivated vaccines might lack adequate cross-protection among different viral strains, especially for the unknown and newly identified strains. Live-attenuated vaccines are produced by reducing or eliminating the virulence of a live virus, typically using chemical-driven, site mutation or gene deletion. Although the live-attenuated vaccine can elicit both innate and adaptive immune responses in mice and hamsters, risk of phenotypic or genotypic reversion and disseminated infection in immunocompromised patients limit further translation [<xref rid="CIT0001" ref-type="bibr">1</xref>].
<table-wrap id="T0004" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Experimental animals for development of SARS-CoV and MERS-CoV vaccines.</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead valign="bottom"><tr><th align="left">Vaccine type</th><th align="center">Design strategy</th><th colspan="2" align="center">Animal models and examples</th><th align="center">Advantages</th><th align="center">Disadvantages</th></tr><tr><th align="left">&#x000a0;</th><th align="center">&#x000a0;</th><th align="center">SARS-CoV</th><th align="center">MERS-CoV</th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th></tr></thead><tbody><tr><td align="left">Inactivated particle</td><td align="left">Whole virus inactivated by heat, chemicals, or radiation</td><td align="left">African green monkeys, rhesus and cynomolgus macaques; BALB/c, C57B6 and 129S6/SvEv mice; ferrets; rabbits</td><td align="left">BALB/c mice</td><td align="left">Rapid and easy for development; safety; high-titre NAbs; protective when used with adjuvant</td><td align="left">Induction of inflammatory immune pathology and ADE; possibly incomplete protection</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">Live-attenuated particle</td><td align="left">Attenuated the virulence by viral genome mutagenesis or targeted deletions</td><td align="left">BALB/c mice; hACE2-Tg mice; hamsters</td><td align="left">BALB/c mice</td><td align="left">Inexpensive; quick immunity; less adverse effect; comprehensive activation of host immunity; multiple targets</td><td align="left">Risk of phenotypic or genotypic reversion and disseminated infection in immunocompromised patients</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">Vector</td><td align="left">Viral vectors that express S or the S1 subunit</td><td align="left">BALB/c and 129S6/SvEv mice; hamsters; ferrets</td><td align="left">BALB/c mice; hDPP4-Tg or transfected mice; dromedary camels</td><td align="left">Comprehensive, Stronger and specific activation of host immunity; high-titre NAbs; safety</td><td align="left">Varied and skewed immune responses; possibly incomplete protection</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">Virus-like particle</td><td align="left">Virus-like replicon particles containing S protein</td><td align="left">BALB/c mice</td><td align="left">Ad-hDPP4 mice; BALB/c mice</td><td align="left">Induction of antiviral T cell responses and S protein specific NAbs; reduce viral titres in lungs to nearly undetectable levels by one after inoculation with MERS-CoV</td><td align="left">&#x000a0;Varied and skewed immune responses; risk of ADE; possibly incomplete protection</td></tr><tr><td align="left">Nanoparticle</td><td align="left">Purified S protein-containing nanoparticles; Gold nanoparticle adjuvanted S protein</td><td align="left">BALB/c mice</td><td align="left">BALB/c mice</td><td align="left">Induction of S protein specific NAbs</td><td align="left">Need appropriate adjuvants; Varied and skewed immune responses; risk of ADE</td></tr><tr><td align="left">Viral subunit</td><td align="left">Antigenic components, whole or separate (S and N protein)</td><td align="left">Rhesus macaques, BALB/c mice and rabbits</td><td align="left">Rhesus macaques; hDPP4 transgenic mice; BALB/c mice</td><td align="left">High safety; consistent production; Comprehensive, Stronger and specific activation of host immunity; high-titre NAbs</td><td align="left">Uncertain cost-effectiveness; mild immunogenicity; need appropriate adjuvants; risk of ADE</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">DNA plasmid</td><td align="left">DNA plasmids that encode S and N protein</td><td align="left">BALB/c mice</td><td align="left">Rhesus macaques and BALB/c mice; Ad-hDPP4 mice</td><td align="left">Easier to design; high safety; high-titre NAbs</td><td align="left">Lower and skewed immune responses; possibly delayed-type hypersensitivity</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table></table-wrap></p><p>Among all the functional structural proteins of coronavirus, the S protein is an important antigen that might effectively inducing NAbs to block viral binding and entry, as well as stimulating robust host immune responses [<xref rid="CIT0058" ref-type="bibr">58</xref>]. Therefore, the S protein has been designed as the main target for the development of SARS vaccines by different strategies including developing a S subunit, using an expression vector, packaging a virus-like particle, delivering a DNA plasmid and nanoparticle [<xref rid="CIT0003" ref-type="bibr">3</xref>]. These vaccine strategies showed protection effects in different animals (<xref rid="T0004" ref-type="table">Table 4</xref>). However, they are limited by the possibilities of incomplete protection, the risk of antibody dependent enhancement (ADE) include expanded infection, tissue destruction, cytokine storm and multiple organ failure [<xref rid="CIT0003" ref-type="bibr">3</xref>]. The mechanism of ADE effect is complicated and not yet clearly clarified. Serum of inactivated SARS-CoV and S protein immunized mice, as well as the S protein specific antibodies were demonstrated to promote viral infection and cytopathogenesis in human immune cells such as macrophage and B lymphocytes, via a pH- and cysteine protease-independent Fc&#x003b3; receptor pathway [<xref rid="CIT0059" ref-type="bibr">59</xref>]. Moreover, S protein specific antibodies treatment caused fatal acute lung injury in SARS-CoV infected NHPs by skewing macrophage mediated inflammation-resolving responses [<xref rid="CIT0060" ref-type="bibr">60</xref>]. In addition, prior immunization with N protein might also cause severe pneumonia in mice infected with live SARS-CoV [<xref rid="CIT0061" ref-type="bibr">61</xref>]. Indeed, many studies showed that virus-like particle, inactivated virus vaccine, rDNA-produced S protein vaccine led to occurrence of pulmonary and Th2-type immunopathology on challenge with live SARS-CoV in mice, suggesting hypersensitivity to SARS-CoV components was induced [<xref rid="CIT0057" ref-type="bibr">57</xref>,<xref rid="CIT0062" ref-type="bibr">62</xref>]. Similar lung immunopathology was also observed in mice immunized with inactivated MERS-CoV vaccine [<xref rid="CIT0063" ref-type="bibr">63</xref>]. These findings suggested that a potential pathogenic effect of antibodies targeted at SARS-CoV-2 would be of major concern for vaccine development and antibody-based therapies.</p><p>Although the NHPs were supposed to be closer to human, different mouse models and MA viral strains have occupied a large proportion of these coronavirus vaccine studies for their advantages of convent and large-scale to draw a more robust conclusion. Due to the genetic differences, the results from animals are not necessarily going to be the same in humans. To the contrary, many vaccines that are effective in animal experiments but showed inadequate protective effects in humans, such as RSV [<xref rid="CIT0064" ref-type="bibr">64</xref>] and HIV [<xref rid="CIT0065" ref-type="bibr">65</xref>]. Nevertheless, animal experiments are the essential step before trials in human for any vaccines.</p></sec><sec id="S006"><title>Animal studies of therapeutic agents</title><p>More than a dozen anti-CoV drugs have been tested <italic>in vitro</italic> and <italic>in vivo</italic>. Targeting protease and RNA-dependent RNA polymerase (RdRp) are the two of the most effective approaches for inhibition of viral replication. Mycophenolic acid, an inhibitor of inosine-monophosphate dehydrogenase and guanine monophosphate synthesis, displayed a potential anti-MERS-CoV activity in cell culture [<xref rid="CIT0066" ref-type="bibr">66</xref>]. However, in an animal study the MERS-CoV infected common marmosets treated with mycophenolate mofetil presented a worse outcome with more severe disease and higher viral loads in necropsied lung than those without treatment [<xref rid="CIT0067" ref-type="bibr">67</xref>]. Ribavirin targeting RdRp and Lopinavir-Ritonavir that targeting 3CLpro protease were approved to treat SARS-CoV and MERS-CoV patients, respectively. Nevertheless, these drugs showed limited antiviral effects upon monotherapy and have severe side effects on patients and animals including rhesus macaques, common marmosets and mice. In recent studies, Remdesivir, a broad spectrum antiviral nucleotide prodrug showed a better anti-MERS-CoV activity than Lopinavir and Ritonavir in both in cell culture study and animal studies (hDPP4 transgenic mice and NHPs) [<xref rid="CIT0068" ref-type="bibr">68</xref>,<xref rid="CIT0069" ref-type="bibr">69</xref>]. Notably, the in vitro anti-SARS-CoV-2 activity of Remdesivir has been demonstrated in a cell culture study [<xref rid="CIT0070" ref-type="bibr">70</xref>]. The RBD site of the S protein is the most important target for development of NAbs [<xref rid="CIT0058" ref-type="bibr">58</xref>]. These NAbs have been well evaluated in animal models including rhesus macaques and common marmoset, mice, rabbits, ferrets and hamster. However, like the vaccines, abnormal immune responses and ADE effects induced by the antibodies remain to be a serious issue [<xref rid="CIT0060" ref-type="bibr">60</xref>].</p><p>The interferon signalling is a double-edged sword for therapy of coronavirus infection. On one hand, recombinant interferons showed preventive and antiviral effects in animal models include cynomolgus and rhesus macaques and common marmosets, mice and ferrets at the early stage of SARS-CoV and MERS-CoV infection. Combined action of type I and type III interferon restricts initial replication of SARS-CoV in the lung but fails to inhibit systemic virus spreading in mice [<xref rid="CIT0045" ref-type="bibr">45</xref>]. On another hand, delayed administration of interferons induce dysregulated interferon signalling and inflammatory monocyte macrophages responses which cause severe transformation and lethal pneumonia in SARS-CoV infected mice [<xref rid="CIT0071" ref-type="bibr">71</xref>]. These experimental findings suggested that a precision intervention time is important for interferon therapy of coronavirus infection.</p><p>Hormones that used to restore cytokine storm and other host signalling pathways involved in viral replication might also considered as options to treat coronavirus infection, but only a few of them were evaluated in mice [<xref rid="CIT0072" ref-type="bibr">72</xref>]. Moreover, old and new drugs associated with host endosomal, surface and other proteases utilized for viral entry, host receptors mediated viral entry, endocytosis and endosomal acidification also showed ability to inhibit coronavirus infection in cell models, respectively. Nevertheless, unknown in vivo antiviral effects, risk of toxicity and adverse effects might limit their further translation. For example, chloroquine which has been demonstrated able to inhibit viral replication of SARS-CoV and SARS-CoV-2 in vitro, but showed no significant therapeutic effect against SARS-CoV in mice model [<xref rid="CIT0073" ref-type="bibr">73</xref>]. Other therapy strategies such as the convalescent-phase plasma still lack mechanism study or detailed in vivo evaluation because the lack of adequate or appropriate animal models. Additionally, testing the antiviral ability of old drugs such as Metformin, Atorvastin, Glitazones, Fibrates and Sartans might be another option at this urgent moment [<xref rid="CIT0074" ref-type="bibr">74</xref>]. Clinically, the combined use of several antiviral drugs and host target agents may be more effective than using either modality alone. For example, SARS-CoV patients who received Ribavirin, Lopinavir-Ritonavir and a corticosteroid had lower 21-day SARD and death rates than those who received ribavirin and a corticosteroid [<xref rid="CIT0075" ref-type="bibr">75</xref>]. Regards to the patients with severe MERS-CoV infection, viremia was resolved within two days after combined treatment of Ribavirin, Lopinavir-Ritonavir and interferon-&#x003b1; [<xref rid="CIT0076" ref-type="bibr">76</xref>].</p><p>In sum, we should learn from the lessons of many previous animal experiments. Firstly, a drug with antiviral effects <italic>in vitro</italic> does not necessarily have antiviral effects <italic>in vivo</italic>. Secondly, combination of two or more drugs that have different antiviral mechanisms might achieve a synergistic or an enhanced therapeutic effect. Thirdly, to know the advantages and disadvantages, all the drugs need to be systematically evaluated in several different animal models before clinical study.</p></sec><sec id="S007"><title>Humanized animal models for studying coronavirus infection</title><p>Prevention of and recovery from the coronavirus infection are usually associated with adaptive and innate immunity. The outcomes of the coronavirus infection depend on humoral immune responses such as the subtype and titre of antibody. Although NHPs, mice and other experimental animals can effectively mimic coronavirus infection, the genetic diversity might disturb the interpretation of the possibly different results between human and non-human species. To directly study coronavirus infection in human organ or tissue, humanized animal models are the method of choice, which can also be used for evaluation of coronavirus vaccines and host target agents. In the past decades, mice with one or several human tissues or cells engraftment have been widely used to investigate the pathogenesis of HIV, HBV, HCV, CMV, varicella-zoster virus (VZV) and other important pathogens.</p><p>Lung is the main target organ of coronavirus infection. In 2012, Maidji et al. grafted human fetal lung tissues under the kidney capsule of immunodeficient SCID mice [<xref rid="CIT0077" ref-type="bibr">77</xref>]. The lung tissues rapidly grew and developed mature structures resembling the normal human lung and were demonstrated to support CMV infection and pathogenesis. In 2017, Wang et al. established a human lung-xenografted mouse model for VZV infection [<xref rid="CIT0078" ref-type="bibr">78</xref>]. After VZV infection, viral replication, lung pathogenies and pro-inflammatory cytokine responses were detected in the human lung xenografts. More recently, Wahl et al. reported a humanized mouse with mono human lung engraftment (LoM) or incorporated with human bone marrow, liver and thymus (BLT-L) [<xref rid="CIT0079" ref-type="bibr">79</xref>]. The LoM or BLT-L mice supports infection and replication of human pathogens such as MERS-CoV, RSV, CMV and Zika virus [<xref rid="CIT0079" ref-type="bibr">79</xref>]. Antigen-specific humoral and T-cell responses were observed in BLT-L mice, suggesting that human lung and immune cell dual chimeric mice might be an ideal humanized animal model for the pathogenesis and immune study of SARS-CoV-2. Due to the abundant expression of hACE2 in multiple organs of human, multiple organs and tissues including liver, heart, intestine, kidney, bladder and immune cells are susceptible to the infection of SARS-CoV-2, suggesting a reason that causes multi-organ failures. Therefore, mice with engraftment of human somatic, progenitor and stem cells, as well as varied human tissues and organoids might be useful to investigate the tropism of SARS-CoV-2.</p><p>Comparing to the traditional animal models, the humanized mice provide new options for investigators to directly study the viral infection in human tissues, which is adequate to delineate the tissue tropism and the host-virus interactions. The development of humanized mice is important to improve our fundamental understanding for mechanisms of coronavirus infection and immunopathophysiology. In the future, humanized mice might become a unique tool to obtain the insights into our strategies for developing coronavirus vaccine, early intervention and antiviral therapy.</p></sec><sec id="S008"><title>Conclusion</title><p>The coronaviruses are one of the most important pathogens causing robust respiratory infection, severe cases and deaths in humans. Here, we input key words including coronavirus, animal model, SARS-CoV, MERS-CoV, SARS-CoV-2 (also named 2019-nCoV in the early stage), SARD and COVID-19 to screen the published articles from PubMed. The most related articles have been cited in this review. Recent proceedings and important data of the coronavirus studies are summarized. We suggested that a rapid animal test of SARS-CoV-2 is important to assess the efficiencies of the vaccines, antivirals and the sensitivity of the diagnostic tests. We also debated that a rapid generation of MA viral strains or mice carrying human receptor is a good option for urgent and effective animal studies. In addition, development of humanized animal model might provide a direct infection of coronavirus to human tissue. Taken together, animal models are the fundamental tolls to investigate the viral pathogenesis, to develop vaccines and antiviral drugs.</p></sec></body><back><sec><title>Acknowledgments</title><p>This work was supported by the National Science and Technology Major Projects for Major New Drugs Innovation and Development (No. 2018ZX09711003-005-003), the National Science and Technology Major Project of Infectious Diseases (No. 2017ZX10304402), Key Research Program of the Ministry of Science and Technology (2020YFC0842600) and the Science and technology project of Fujian Province (2020YZ0106). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec><sec id="S009"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec id="S010"><title>ORCID</title><p><italic>Qiyi Tang</italic>
<ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-6487-2356">http://orcid.org/0000-0002-6487-2356</ext-link></p><p><italic>Tong Cheng</italic>
<ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0002-1638-6214">http://orcid.org/0000-0002-1638-6214</ext-link></p><p><italic>Ningshao Xia</italic>
<ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0003-0179-5266">http://orcid.org/0000-0003-0179-5266</ext-link></p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Donaldson</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Baric</surname><given-names>RS.</given-names></name></person-group>
<article-title>A decade after SARS: strategies for controlling emerging coronaviruses</article-title>. <source>Nat Rev Microbiol</source>. <year>2013 Dec</year>;<volume>11</volume>(<issue>12</issue>):<fpage>836</fpage>&#x02013;<lpage>848</lpage>.<pub-id pub-id-type="pmid">24217413</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>. <source>Nat Rev Microbiol</source>. <year>2016 Aug</year>;<volume>14</volume>(<issue>8</issue>):<fpage>523</fpage>&#x02013;<lpage>534</lpage>.<pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Azhar</surname><given-names>EI</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Coronaviruses &#x02013; drug discovery and therapeutic options</article-title>. <source>Nat Rev Drug Discovery</source>. <year>2016 May</year>;<volume>15</volume>(<issue>5</issue>):<fpage>327</fpage>&#x02013;<lpage>347</lpage>.<pub-id pub-id-type="pmid">26868298</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ksiazek</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Erdman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Goldsmith</surname><given-names>CS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title>. <source>N Engl J Med</source>. <year>2003 May 15</year>;<volume>348</volume>(<issue>20</issue>):<fpage>1953</fpage>&#x02013;<lpage>1966</lpage>.<pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assiri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Al-Tawfiq</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Al-Rabeeah</surname><given-names>AA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study</article-title>. <source>Lancet Infect Dis</source>. <year>2013 Sep</year>;<volume>13</volume>(<issue>9</issue>):<fpage>752</fpage>&#x02013;<lpage>761</lpage>.<pub-id pub-id-type="pmid">23891402</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Horby</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Hayden</surname><given-names>FG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A novel coronavirus outbreak of global health concern</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>470</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">31986257</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>XG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7798</issue>):<fpage>270</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>497</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>ZY</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>18</issue>):<fpage>1708</fpage>&#x02013;<lpage>1720</lpage>.<pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gou</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<comment>Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints. 2020</comment>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<comment>Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. medRxiv preprint. 2020</comment>.</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>McAuliffe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice</article-title>. <source>J Virol</source>. <year>2004 Apr</year>;<volume>78</volume>(<issue>7</issue>):<fpage>3572</fpage>&#x02013;<lpage>3577</lpage>.<pub-id pub-id-type="pmid">15016880</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockrell</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Peck</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Yount</surname><given-names>BL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection</article-title>. <source>J Virol</source>. <year>2014 May</year>;<volume>88</volume>(<issue>9</issue>):<fpage>5195</fpage>&#x02013;<lpage>5199</lpage>.<pub-id pub-id-type="pmid">24574399</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2</article-title>. <source>Science</source>. <year>2020</year>
<fpage>pii: eabb7015</fpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gretebeck</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group>
<article-title>Animal models for SARS and MERS coronaviruses</article-title>. <source>Curr Opin Virol</source>. <year>2015 Aug</year>;<volume>13</volume>:<fpage>123</fpage>&#x02013;<lpage>129</lpage>.<pub-id pub-id-type="pmid">26184451</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutton</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group>
<article-title>Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus</article-title>. <source>Virology</source>. <year>2015 May</year>;<volume>479-480</volume>:<fpage>247</fpage>&#x02013;<lpage>258</lpage>.<pub-id pub-id-type="pmid">25791336</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAuliffe</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys</article-title>. <source>Virology</source>. <year>2004 Dec 5</year>;<volume>330</volume>(<issue>1</issue>):<fpage>8</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">15527829</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Q</given-names></name>, <etal>et al.</etal></person-group>
<article-title>An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus</article-title>. <source>J Pathol</source>. <year>2005 Jul</year>;<volume>206</volume>(<issue>3</issue>):<fpage>251</fpage>&#x02013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">15892035</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenough</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Carville</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Coderre</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus</article-title>. <source>Am J Pathol</source>. <year>2005 Aug</year>;<volume>167</volume>(<issue>2</issue>):<fpage>455</fpage>&#x02013;<lpage>463</lpage>.<pub-id pub-id-type="pmid">16049331</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Infection with MERS-CoV causes lethal pneumonia in the common marmoset</article-title>. <source>PLoS Pathog</source>. <year>2014 Aug</year>;<volume>10</volume>(<issue>8</issue>):<fpage>e1004250</fpage>.<pub-id pub-id-type="pmid">25144235</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rasmussen</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013 Oct 8</year>;<volume>110</volume>(<issue>41</issue>):<fpage>16598</fpage>&#x02013;<lpage>16603</lpage>.<pub-id pub-id-type="pmid">24062443</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<comment>Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route. bioRxiv preprint. 2020</comment>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<comment>Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv preprint. 2020</comment>.</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<comment>Comparison of SARS-CoV-2 infections among 3 species of non-human primates. bioRxiv preprint. 2020</comment>.</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martina</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Kuiken</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Virology: SARS virus infection of cats and ferrets</article-title>. <source>Nature</source>. <year>2003 Oct 30</year>;<volume>425</volume>(<issue>6961</issue>):<fpage>915</fpage>.<pub-id pub-id-type="pmid">14586458</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>Smits</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Provacia</surname><given-names>LB</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus</article-title>. <source>J Virol</source>. <year>2014 Feb</year>;<volume>88</volume>(<issue>3</issue>):<fpage>1834</fpage>&#x02013;<lpage>1838</lpage>.<pub-id pub-id-type="pmid">24257613</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YI</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Infection and rapid transmission of SARS-CoV-2 in ferrets</article-title>. <source>Cell Host Microbe</source>. <year>2020</year>. pii:S1931-3128(20)30187-6.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Prescott</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baseler</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>):<fpage>e69127</fpage>.<pub-id pub-id-type="pmid">23844250</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>. pii: ciaa325.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>van den Brand</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Provacia</surname><given-names>LB</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits</article-title>. <source>J Virol</source>. <year>2015 Jun</year>;<volume>89</volume>(<issue>11</issue>):<fpage>6131</fpage>&#x02013;<lpage>6135</lpage>.<pub-id pub-id-type="pmid">25810539</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCray</surname><given-names>PB</given-names><suffix>Jr.</suffix></name>, <name name-style="western"><surname>Pewe</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus</article-title>. <source>J Virol</source>. <year>2007 Jan</year>;<volume>81</volume>(<issue>2</issue>):<fpage>813</fpage>&#x02013;<lpage>821</lpage>.<pub-id pub-id-type="pmid">17079315</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Newman</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor</article-title>. <source>J Virol</source>. <year>2007 Feb</year>;<volume>81</volume>(<issue>3</issue>):<fpage>1162</fpage>&#x02013;<lpage>1173</lpage>.<pub-id pub-id-type="pmid">17108019</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>XH</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection</article-title>. <source>Comp Med</source>. <year>2007 Oct</year>;<volume>57</volume>(<issue>5</issue>):<fpage>450</fpage>&#x02013;<lpage>459</lpage>.<pub-id pub-id-type="pmid">17974127</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshikawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yoshikawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human angiotensin-converting enzyme 2</article-title>. <source>J Virol</source>. <year>2009 Jun</year>;<volume>83</volume>(<issue>11</issue>):<fpage>5451</fpage>&#x02013;<lpage>5465</lpage>.<pub-id pub-id-type="pmid">19297479</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Garron</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease</article-title>. <source>J Virol</source>. <year>2015 Apr</year>;<volume>89</volume>(<issue>7</issue>):<fpage>3659</fpage>&#x02013;<lpage>3670</lpage>.<pub-id pub-id-type="pmid">25589660</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wohlford-Lenane</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2017 Apr 11</year>;<volume>114</volume>(<issue>15</issue>):<fpage>E3119</fpage>&#x02013;<lpage>E3128</lpage>.<pub-id pub-id-type="pmid">28348219</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Okamura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shimizu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Acute respiratory infection in human dipeptidyl peptidase 4-transgenic mice infected with Middle East respiratory syndrome coronavirus</article-title>. <source>J Virol</source>. <year>2019</year>;<volume>93</volume>(<issue>6</issue>). pii:e01818-18.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<comment>The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice. bioRxiv preprint. 2020</comment>.</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frieman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yount</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease</article-title>. <source>J Virol</source>. <year>2012 Jan</year>;<volume>86</volume>(<issue>2</issue>):<fpage>884</fpage>&#x02013;<lpage>897</lpage>.<pub-id pub-id-type="pmid">22072787</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Whittaker</surname><given-names>GR.</given-names></name></person-group>
<article-title>Host cell proteases: critical determinants of coronavirus tropism and pathogenesis</article-title>. <source>Virus Res</source>. <year>2015 Apr 16</year>;<volume>202</volume>:<fpage>120</fpage>&#x02013;<lpage>134</lpage>.<pub-id pub-id-type="pmid">25445340</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schroeder</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source>. <year>2020</year>;<volume>18</volume>(<issue>2</issue>):<fpage>271</fpage>&#x02013;<lpage>280</lpage>.</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Barlan</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2016 Oct 25</year>;<volume>113</volume>(<issue>43</issue>):<fpage>12262</fpage>&#x02013;1226<lpage>7</lpage>.<pub-id pub-id-type="pmid">27791014</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>WG</given-names></name>, <name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>B</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice</article-title>. <source>J Immunol</source>. <year>2004 Sep 15</year>;<volume>173</volume>(<issue>6</issue>):<fpage>4030</fpage>&#x02013;<lpage>4039</lpage>.<pub-id pub-id-type="pmid">15356152</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogan</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rowe</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1</article-title>. <source>J Virol</source>. <year>2004 Oct</year>;<volume>78</volume>(<issue>20</issue>):<fpage>11416</fpage>&#x02013;<lpage>11421</lpage>.<pub-id pub-id-type="pmid">15452265</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahlakoiv</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ritz</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mordstein</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread</article-title>. <source>J Gen Virol</source>. <year>2012 Dec</year>;<volume>93</volume>(<issue>Pt 12</issue>):<fpage>2601</fpage>&#x02013;<lpage>2605</lpage>.<pub-id pub-id-type="pmid">22956738</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Matthews</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Goicochea</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus</article-title>. <source>J Gen Virol</source>. <year>2014 Feb</year>;<volume>95</volume>(<issue>Pt 2</issue>):<fpage>408</fpage>&#x02013;<lpage>412</lpage>.<pub-id pub-id-type="pmid">24197535</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10229</issue>):<fpage>1054</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Paddock</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans</article-title>. <source>J Virol</source>. <year>2005 May</year>;<volume>79</volume>(<issue>9</issue>):<fpage>5833</fpage>&#x02013;<lpage>5838</lpage>.<pub-id pub-id-type="pmid">15827197</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Vogel</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Animal models and vaccines for SARS-CoV infection</article-title>. <source>Virus Res</source>. <year>2008 Apr</year>;<volume>133</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">17499378</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fett</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mack</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection</article-title>. <source>J Immunol</source>. <year>2017 May 15</year>;<volume>198</volume>(<issue>10</issue>):<fpage>4046</fpage>&#x02013;<lpage>4053</lpage>.<pub-id pub-id-type="pmid">28373583</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vijay</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection</article-title>. <source>J Exp Med</source>. <year>2015 Oct 19</year>;<volume>212</volume>(<issue>11</issue>):<fpage>1851</fpage>&#x02013;<lpage>1868</lpage>.<pub-id pub-id-type="pmid">26392224</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection</article-title>. <source>J Virol</source>. <year>2010 Feb</year>;<volume>84</volume>(<issue>3</issue>):<fpage>1289</fpage>&#x02013;<lpage>1301</lpage>.<pub-id pub-id-type="pmid">19906920</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kok</surname><given-names>KH</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>514</fpage>&#x02013;<lpage>523</lpage>.<pub-id pub-id-type="pmid">31986261</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="standard"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>ZX</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<comment>Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan SARS-CoV-2. bioRxiv preprint. 2020</comment>.</mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlberg</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chong</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>WY.</given-names></name></person-group>
<article-title>Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?</article-title>
<source>Am J Epidemiol</source>. <year>2004</year>;<volume>159</volume>(<issue>3</issue>):<fpage>229</fpage>&#x02013;<lpage>231</lpage>.<pub-id pub-id-type="pmid">14742282</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alghamdi</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Hussain</surname><given-names>II</given-names></name>, <name name-style="western"><surname>Almalki</surname><given-names>SS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health</article-title>. <source>Int J Gen Med</source>. <year>2014</year>;<volume>7</volume>:<fpage>417</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">25187734</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Deming</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title>. <source>J Virol</source>. <year>2011 Dec</year>;<volume>85</volume>(<issue>23</issue>):<fpage>12201</fpage>&#x02013;<lpage>12215</lpage>.<pub-id pub-id-type="pmid">21937658</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The spike protein of SARS-CoV &#x02014; a target for vaccine and therapeutic development</article-title>. <source>Nat Rev Microbiol</source>. <year>2009 Mar</year>;<volume>7</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">19198616</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaume</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yip</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>CY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway</article-title>. <source>J Virol</source>. <year>2011 Oct</year>;<volume>85</volume>(<issue>20</issue>):<fpage>10582</fpage>&#x02013;<lpage>10597</lpage>.<pub-id pub-id-type="pmid">21775467</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title>. <source>JCI Insight</source>. <year>2019</year>;<volume>4</volume>(<issue>4</issue>). pii:123158.</mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasui</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kai</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kitabatake</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV</article-title>. <source>J Immunol</source>. <year>2008 Nov 1</year>;<volume>181</volume>(<issue>9</issue>):<fpage>6337</fpage>&#x02013;<lpage>6348</lpage>.<pub-id pub-id-type="pmid">18941225</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Sbrana</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title>. <source>PloS one</source>. <year>2012</year>;<volume>7</volume>(<issue>4</issue>):<fpage>e35421</fpage>.<pub-id pub-id-type="pmid">22536382</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title>. <source>Hum Vaccin Immunother</source>. <year>2016 Sep</year>;<volume>12</volume>(<issue>9</issue>):<fpage>2351</fpage>&#x02013;<lpage>2356</lpage>.<pub-id pub-id-type="pmid">27269431</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Magoffin</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Shearer</surname><given-names>LA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population</article-title>. <source>Am J Epidemiol</source>. <year>1969 Apr</year>;<volume>89</volume>(<issue>4</issue>):<fpage>449</fpage>&#x02013;<lpage>463</lpage>.<pub-id pub-id-type="pmid">4305200</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekker</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Tatoud</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dabis</surname><given-names>F</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The complex challenges of HIV vaccine development require renewed and expanded global commitment</article-title>. <source>Lancet</source>. <year>2020 Feb 1</year>;<volume>395</volume>(<issue>10221</issue>):<fpage>384</fpage>&#x02013;<lpage>388</lpage>.<pub-id pub-id-type="pmid">31806257</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Kao</surname><given-names>RY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus</article-title>. <source>J Infect</source>. <year>2013 Dec</year>;<volume>67</volume>(<issue>6</issue>):<fpage>606</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="pmid">24096239</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yeung</surname><given-names>ML</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset</article-title>. <source>J Infect Dis</source>. <year>2015 Dec 15</year>;<volume>212</volume>(<issue>12</issue>):<fpage>1904</fpage>&#x02013;<lpage>1913</lpage>.<pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheahan</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Sims</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Leist</surname><given-names>SR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title>. <source>Nat Commun</source>. <year>2020 Jan 10</year>;<volume>11</volume>(<issue>1</issue>):<fpage>222</fpage>.<pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cronin</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2020</year>;<volume>117</volume>(<issue>12</issue>):<fpage>6771</fpage>&#x02013;<lpage>6776</lpage>.<pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>. <source>Cell Res</source>. <year>2020</year>;<volume>30</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fehr</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Vijay</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title>. <source>Cell Host Microbe</source>. <year>2016 Feb 10</year>;<volume>19</volume>(<issue>2</issue>):<fpage>181</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Vedantham</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Protease inhibitors targeting coronavirus and filovirus entry</article-title>. <source>Antiviral Res</source>. <year>2015 Apr</year>;<volume>116</volume>:<fpage>76</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">25666761</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnard</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Evaluation of immunomodulators, interferons and known <italic>in vitro</italic> SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice</article-title>. <source>Antiviral Chem Chemother</source>. <year>2006</year>;<volume>17</volume>(<issue>5</issue>):<fpage>275</fpage>&#x02013;<lpage>284</lpage>.</mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Azhar</surname><given-names>EI</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Reducing mortality from 2019-nCoV: host-directed therapies should be an option</article-title>. <source>Lancet</source>. <year>2020 February 22</year>;<volume>395</volume>(<issue>10224</issue>):<fpage>e35</fpage>&#x02013;<lpage>e36</lpage>.<pub-id pub-id-type="pmid">32035018</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>CM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study</article-title>. <source>Hong Kong Med J = Xianggang yi xue za zhi</source>. <year>2003 Dec</year>;<volume>9</volume>(<issue>6</issue>):<fpage>399</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">14660806</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spanakis</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tsiodras</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen</article-title>. <source>Int J Antimicrob Agents</source>. <year>2014 Dec</year>;<volume>44</volume>(<issue>6</issue>):<fpage>528</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">25288266</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maidji</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kosikova</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Joshi</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Impaired surfactant production by alveolar epithelial cells in a SCID-hu lung mouse model of congenital human cytomegalovirus infection</article-title>. <source>J Virol</source>. <year>2012 Dec</year>;<volume>86</volume>(<issue>23</issue>):<fpage>12795</fpage>&#x02013;<lpage>12805</lpage>.<pub-id pub-id-type="pmid">22973041</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A SCID mouse-human lung xenograft model of varicella-zoster virus infection</article-title>. <source>Antiviral Res</source>. <year>2017 Oct</year>;<volume>146</volume>:<fpage>45</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">28827121</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahl</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Abad Fernandez</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Precision mouse models with expanded tropism for human pathogens</article-title>. <source>Nat Biotechnol</source>. <year>2019 Oct</year>;<volume>37</volume>(<issue>10</issue>):<fpage>1163</fpage>&#x02013;<lpage>1173</lpage>.<pub-id pub-id-type="pmid">31451733</pub-id></mixed-citation></ref></ref-list></back></article>